Caligan Partners LP Acquires Shares of 752,167 ABIVAX Société Anonyme (NASDAQ:ABVX)

Caligan Partners LP purchased a new position in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 752,167 shares of the company's stock, valued at approximately $5,506,000. ABIVAX Société Anonyme makes up about 1.5% of Caligan Partners LP's portfolio, making the stock its 12th biggest holding. Caligan Partners LP owned approximately 1.19% of ABIVAX Société Anonyme as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. ADAR1 Capital Management LLC lifted its position in shares of ABIVAX Société Anonyme by 190.1% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company's stock worth $11,078,000 after purchasing an additional 991,781 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in ABIVAX Société Anonyme in the 4th quarter valued at approximately $5,336,000. Nantahala Capital Management LLC boosted its stake in ABIVAX Société Anonyme by 45.7% during the fourth quarter. Nantahala Capital Management LLC now owns 1,436,047 shares of the company's stock worth $10,512,000 after buying an additional 450,413 shares in the last quarter. Boothbay Fund Management LLC acquired a new stake in ABIVAX Société Anonyme during the fourth quarter valued at approximately $2,979,000. Finally, Springhill Fund Asset Management HK Co Ltd acquired a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth approximately $1,520,000. Institutional investors and hedge funds own 47.91% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Morgan Stanley reaffirmed an "equal weight" rating and issued a $12.00 price objective on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th. JMP Securities reiterated a "market outperform" rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Wednesday, April 30th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $34.00.

ABIVAX Société Anonyme Trading Down 3.7 %

Shares of ABIVAX Société Anonyme stock traded down $0.26 during trading hours on Tuesday, hitting $6.86. 142,975 shares of the company's stock traded hands, compared to its average volume of 132,339. The company has a fifty day simple moving average of $6.59 and a 200-day simple moving average of $7.48. ABIVAX Société Anonyme has a 12-month low of $4.77 and a 12-month high of $15.06.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.